Early Phase 1 Inflammatory Clinical Trials
13 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–13 of 13 trials
Recruiting
Early Phase 1
MTS109 in Patients With Refractory Autoimmune Diseases
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Early Phase 1
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies
CytoCares Inc6 enrolled1 locationNCT07193810
Recruiting
Early Phase 1
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Inflammatory Bowel DiseasesPrimary Sclerosing Cholangitis
Stanford University15 enrolled1 locationNCT05912387
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting
Early Phase 1
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Idiopathic Inflammatory MyopathiesSporadic Inclusion Body Myositis (sIBM)
Austin Neuromuscular Center10 enrolled2 locationsNCT06479863
Recruiting
Early Phase 1
GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
Idiopathic Inflammatory Myopathy (IIM)
Daishi Tian12 enrolled1 locationNCT07086404
Recruiting
Early Phase 1
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Early Phase 1
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting
Early Phase 1
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Idiopathic Inflammatory Myopathies(IIM)
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT07174843
Recruiting
Early Phase 1
Safety Study of CC312 in Autoimmune Disease Patients
Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Early Phase 1
A Clinical Study of SPH7854 Granules in Healthy Subjects.
Inflammatory Bowel Disease
Shanghai Pharmaceuticals Holding Co., Ltd111 enrolled1 locationNCT06483373
Recruiting
Early Phase 1
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557
Completed
Early Phase 1
The buccal administration of a NanoCelle™ Cannabidiol formulation to healthy volunteers: a pharmacokinetic, safety and tolerability exploratory pilot study.
The Investigational Product may be indicated for insomniaThe Investigational Product may be indicated for the treatment of inflammatory painThe Investigational Product may be indicated for mood symptoms+1 more
Medlab Clinical16 enrolled1 locationACTRN12617001491358